Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 188
Filtrar
1.
Am J Cardiol ; 183: 93-98, 2022 11 15.
Artigo em Inglês | MEDLINE | ID: mdl-36114020

RESUMO

Dilated cardiomyopathy associated with lamin A/C (LMNA) gene variants (LMNA-related dilated cardiomyopathy [DCM]) is a life-threatening condition with a high unmet need, accounting for approximately 6% of idiopathic DCM cases. Currently, no disease-specific treatments target the underlying disease mechanism. ARRY-371797 (PF-07265803), a potent, selective, oral, small-molecule inhibitor of the p38α mitogen-activated protein kinase pathway, improved 6-minute walk test (6MWT) distance in 12 patients with symptomatic LMNA-related DCM in a 48-week, open-label, phase 2 study. This long-term extension study examined the safety and efficacy of ARRY-371797 in patients from the phase 2 study. 6MWT, N-terminal pro-B-type natriuretic peptide concentration, and 12-item Kansas City Cardiomyopathy Questionnaire score were assessed at weeks 48, 72, 96, 120, and 144 from phase 2 study baseline. Eight patients enrolled (mean [SD] age, 51 [10] years, 4 male). Mean 6MWT increased by >30 m (>10%) from phase 2 study baseline up to week 120. The decrease in N-terminal pro-B-type natriuretic peptide observed in the phase 2 study was maintained throughout the present study. Twelve-item Kansas City Cardiomyopathy Questionnaire Physical Limitation increased from baseline at all visits except week 96 (range: -0.8 [week 96] to 13.8 [week 120]); results for other domains were variable. Treatment was generally well tolerated; 2 patients discontinued because of causes not considered treatment-related. There were no deaths. ARRY-371797 was generally well tolerated over median (range) 155.7 (61 to 327)-week exposure; evidence suggested preserved exercise capacity over the study period. The ongoing, pivotal, phase 3, randomized, placebo-controlled study REALM-DCM investigates the efficacy and safety of ARRY-371797 (PF-07265803) in LMNA-related DCM. (ClinicalTrials.gov Identifier: NCT02351856).


Assuntos
Cardiomiopatia Dilatada , Etilenodiaminas , Indazóis , Adulto , Cardiomiopatia Dilatada/tratamento farmacológico , Cardiomiopatia Dilatada/genética , Ensaios Clínicos Fase II como Assunto , Ensaios Clínicos Fase III como Assunto , Etilenodiaminas/efeitos adversos , Feminino , Humanos , Indazóis/efeitos adversos , Lamina Tipo A/genética , Lamina Tipo A/metabolismo , Masculino , Pessoa de Meia-Idade , Proteína Quinase 14 Ativada por Mitógeno , Peptídeo Natriurético Encefálico , Ensaios Clínicos Controlados Aleatórios como Assunto
5.
J Pharmacol Sci ; 134(4): 203-210, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28779994

RESUMO

Iron-salen, i.e., µ-oxo-N,N'-bis(salicylidene)ethylenediamine iron (Fe(Salen)) was a recently identified as a new anti-cancer compound with intrinsic magnetic properties. Chelation therapy has been widely used in management of metallic poisoning, because an administration of agents that bind metals can prevent potential lethal effects of particular metal. In this study, we confirmed the therapeutic effect of deferoxamine mesylate (DFO) chelation against Fe(Salen) as part of the chelator antidote efficacy. DFO administration resulted in reduced cytotoxicity and ROS generation by Fe(Salen) in cancer cells. DFO (25 mg/kg) reduced the onset of Fe(Salen) (25 mg/kg)-induced acute liver and renal dysfunction. DFO (300 mg/kg) improves survival rate after systematic injection of a fatal dose of Fe(Salen) (200 mg/kg) in mice. DFO enables the use of higher Fe(Salen) doses to treat progressive states of cancer, and it also appears to decrease the acute side effects of Fe(Salen). This makes DFO a potential antidote candidate for Fe(Salen)-based cancer treatments, and this novel strategy could be widely used in minimally-invasive clinical settings.


Assuntos
Antídotos , Antineoplásicos/efeitos adversos , Antineoplásicos/toxicidade , Quelantes/efeitos adversos , Quelantes/toxicidade , Desferroxamina/farmacologia , Desferroxamina/uso terapêutico , Etilenodiaminas/efeitos adversos , Etilenodiaminas/toxicidade , Quelantes de Ferro/farmacologia , Quelantes de Ferro/uso terapêutico , Ferro/efeitos adversos , Ferro/toxicidade , Injúria Renal Aguda/induzido quimicamente , Animais , Antineoplásicos/administração & dosagem , Quelantes/administração & dosagem , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Relação Dose-Resposta a Droga , Etilenodiaminas/administração & dosagem , Humanos , Ferro/administração & dosagem , Coelhos , Espécies Reativas de Oxigênio/metabolismo , Células Tumorais Cultivadas
7.
Contact Dermatitis ; 75(6): 363-369, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27659009

RESUMO

BACKGROUND: Five workers from a plant manufacturing concrete wall panels and beams were referred to our department because of suspected occupational dermatitis. When patch tested, 3 workers reacted to potassium dichromate. Four workers reacted to ethylenediamine dihydrochloride, without any obvious exposure. Owing to the high proportion of workers with recent-onset skin disease, an investigation of all workers at the plant was initiated. OBJECTIVES: To investigate the prevalence of occupational dermatitis and contact allergy in the workers at the plant. METHODS: All 24 workers at the plant underwent a clinical investigation and were patch tested. RESULTS: Four cases of allergic occupational contact dermatitis and 3 cases of irritant occupational contact dermatitis were diagnosed. Contact allergy to potassium dichromate was found in 4 workers. All 4 also reacted to ethylenediamine dihydrochloride and/or amines that were present as additives in the cement. CONCLUSIONS: Chromate contact allergy can still be found in concrete workers, despite the legislation regulating the amount of hexavalent chromium (chromate) in cement. Occupational contact allergy to amines can be found in workers exposed to cement and concrete, so amines should be tested in these workers.


Assuntos
Materiais de Construção/efeitos adversos , Dermatite Alérgica de Contato/etiologia , Dermatite Irritante/etiologia , Dermatite Ocupacional/etiologia , Etilenodiaminas/efeitos adversos , Exposição Ocupacional/efeitos adversos , Dicromato de Potássio/efeitos adversos , Adulto , Dermatite Alérgica de Contato/diagnóstico , Dermatite Alérgica de Contato/epidemiologia , Dermatite Irritante/diagnóstico , Dermatite Irritante/epidemiologia , Dermatite Ocupacional/diagnóstico , Dermatite Ocupacional/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Suécia
8.
Mol Med Rep ; 12(4): 5973-82, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26238161

RESUMO

The present study investigated the effects of zinc deficiency during in vitro maturation (IVM) of porcine oocytes. Zinc deficiency was induced by administering the membrane­permeable zinc chelator N,N,N',N'­tetrakis­(2­pyridylmethyl)­ethylendiamine (TPEN). First, the effects of zinc deficiency during IVM on a TPEN­treated group and a TPEN+zinc-treated group compared with a control group were assessed. The oocyte maturation rates and subsequent embryonic developmental competence of the TPEN+zinc­treated oocytes were similar to those of the control oocytes (metaphase II [MII] rate, 93.0 and 92.7%, respectively, and blastocyst [BL] formation rate, 42.0 and 40.0%, respectively). These results were significantly different from those obtained for the TPEN­treated oocytes (MII rate, 0.61%; BL formation rate, 0%). Although the TPEN­treated oocytes were arrested at metaphase I (MI), the distribution of microtubules was normal. However, microfilament formation was abnormal in the TPEN­treated oocytes. Furthermore, the effect of a temporary zinc deficiency during IVM on oocyte maturation and subsequent embryonic development was assessed. TPEN (10 µM) was added to the IVM medium for 0, 7, 15 or 22 h. The 0 h­treated oocytes showed an 83.9% MII rate, while the 7 h­treated oocytes had a significantly lower MII rate (44.8%). Most of the 15- and 22 h­treated oocytes were arrested at MI (MI rate: 98.0 and 97.2%, respectively; MII rate, 0% in both groups). Reductions in the BL formation were dependent on the TPEN treatment duration (29.3, 9.2, 0, and 0% after 0, 7, 15 and 22 h, respectively). In conclusion, zinc is an essential element for successful oocyte maturation and embryonic development in pigs. Zinc deficiency caused a meiotic block and had lasting effects on early embryonic development.


Assuntos
Oócitos/efeitos dos fármacos , Zinco/deficiência , Animais , Blastocisto/citologia , Blastocisto/efeitos dos fármacos , Células Cultivadas , Desenvolvimento Embrionário/efeitos dos fármacos , Etilenodiaminas/efeitos adversos , Glutationa/metabolismo , Metáfase , Oócitos/citologia , Espécies Reativas de Oxigênio/metabolismo , Suínos
9.
J Antimicrob Chemother ; 70(5): 1558-66, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25630641

RESUMO

OBJECTIVES: SQ109, an asymmetrical diamine, is a novel anti-TB drug candidate. This first study in patients was done to determine safety, tolerability, pharmacokinetics and bacteriological effect of different doses of SQ109 alone and in combination with rifampicin when administered over 14 days. PATIENTS AND METHODS: Smear-positive pulmonary TB patients were randomized into six groups of 15 to receive once-daily oral treatment with 75, 150 or 300 mg of SQ109, rifampicin (10 mg/kg body weight), rifampicin plus 150 mg of SQ109, or rifampicin plus 300 mg of SQ109 for 14 days. Patients were hospitalized for supervised treatment, regular clinical, biochemical and electrocardiographic safety assessments, pharmacokinetic profiling and daily overnight sputum collection. RESULTS: SQ109 was safe and generally well tolerated. Mild to moderate dose-dependent gastrointestinal complaints were the most frequent adverse events. No relevant QT prolongation was noted. Maximum SQ109 plasma concentrations were lower than MICs. Exposure to SQ109 (AUC0-24) increased by drug accumulation upon repeated administration in the SQ109 monotherapy groups. Co-administration of SQ109 150 mg with rifampicin resulted in decreasing SQ109 exposures from day 1 to day 14. A higher (300 mg) dose of SQ109 largely outweighed the evolving inductive effect of rifampicin. The daily fall in log cfu/mL of sputum (95% CI) was 0.093 (0.126-0.059) with rifampicin, 0.133 (0.166-0.100) with rifampicin plus 150 mg of SQ109 and 0.089 (0.121-0.057) with rifampicin plus 300 mg of SQ109. Treatments with SQ109 alone showed no significant activity. CONCLUSIONS: SQ109 alone or with rifampicin was safe over 14 days. Upon co-administration with rifampicin, 300 mg of SQ109 yielded a higher exposure than the 150 mg dose. SQ109 did not appear to be active alone or to enhance the activity of rifampicin during the 14 days of treatment.


Assuntos
Adamantano/análogos & derivados , Antituberculosos/administração & dosagem , Etilenodiaminas/administração & dosagem , Rifampina/administração & dosagem , Tuberculose Pulmonar/tratamento farmacológico , Adamantano/administração & dosagem , Adamantano/efeitos adversos , Adamantano/farmacocinética , Adulto , Antituberculosos/efeitos adversos , Antituberculosos/farmacocinética , Quimioterapia Combinada/efeitos adversos , Quimioterapia Combinada/métodos , Etilenodiaminas/efeitos adversos , Etilenodiaminas/farmacocinética , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mycobacterium tuberculosis/isolamento & purificação , Rifampina/efeitos adversos , Rifampina/farmacocinética , Escarro/microbiologia , Resultado do Tratamento , Adulto Jovem
10.
Dermatol Online J ; 19(2): 4, 2013 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-23473274

RESUMO

Hydroxyzine is commonly used to treat pruritic skin lesions. Although rare, hydroxyzine can sometimes be linked to worsening dermatitis in patients who have sensitivities to phenothiazines and/or ethylenediamines. Herein we describe a patient who developed papulovesicular eruptions following the use of topical neomycin. Our patient's contact dermatitis initially improved after the use of oral steroids. However, the patient's skin condition was exacerbated by the continued use of hydroxyzine to treat her pruritus. Patch testing was positive at 48 hours for neomycin sulfate, ethylenediamine dihydrochloride, and p-phenylenediamine. Given the suspected cross-reactivity between hydroxyzine and ethylenediamine, hydroxyzine was discontinued and the patient's cutaneous symptoms improved. In summary, physicians must be aware that oral hydroxyzine can worsen contact dermatitis in ethylenediamine-sensitive patients.


Assuntos
Antibacterianos/efeitos adversos , Antipruriginosos/efeitos adversos , Dermatite de Contato/tratamento farmacológico , Hipersensibilidade a Drogas/diagnóstico , Hidroxizina/efeitos adversos , Neomicina/efeitos adversos , Administração Cutânea , Administração Oral , Adulto , Antipruriginosos/administração & dosagem , Etilenodiaminas/efeitos adversos , Feminino , Humanos , Hidroxizina/administração & dosagem
11.
Water Res ; 47(2): 833-40, 2013 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-23206497

RESUMO

This study compares two different solar photo-Fenton processes, conventional photo-Fenton at pH3 and modified photo-Fenton at neutral pH with minimal Fe (5 mg L⁻¹) and minimal initial H2O2 (50 mg L⁻¹) concentrations for the degradation of emerging contaminants in Municipal Wastewater Treatment Plants effluents in solar pilot plant. As Fe precipitates at neutral pH, complexing agents which are able to form photoactive species, do not pollute the environment or increase toxicity have to be used to keep the iron in solution. This study was done using real effluents containing over 60 different contaminants, which were monitored during treatment by liquid chromatography coupled to a hybrid quadrupole/linear ion trap mass analyzer (LC-QTRAP-MS/MS) operating in selected reaction monitoring (SRM) mode. Concentrations of the selected contaminants ranged from a few ng L⁻¹ to tens of µg L⁻¹. It was demonstrated in all cases the removal of over 95% of the contaminants. Photo-Fenton at pH3 provided the best treatment time, but has the disadvantage that the water must be previously acidified. The most promising process was photo-Fenton modified with Ethylenediamine-N,N'-disuccinic acid (EDDS), as the pH remained in the neutral range.


Assuntos
Peróxido de Hidrogênio/química , Ferro/química , Oxidantes Fotoquímicos/química , Luz Solar , Águas Residuárias/química , Poluentes Químicos da Água/química , Purificação da Água/métodos , Cromatografia Líquida de Alta Pressão , Cidades , Etilenodiaminas/efeitos adversos , Etilenodiaminas/química , Concentração de Íons de Hidrogênio , Quelantes de Ferro/efeitos adversos , Quelantes de Ferro/química , Governo Local , Concentração Osmolar , Processos Fotoquímicos , Solubilidade , Espanha , Succinatos/efeitos adversos , Succinatos/química , Espectrometria de Massas em Tandem , Poluentes Químicos da Água/análise
12.
Acta Clin Croat ; 52(4): 515-22, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24697004

RESUMO

We report a case of a patient with acute pancreatitis who developed serious heart rhythm abnormalities on three occasions, two of which were associated with administration of the first generation antihistamine chloropyramine, and the third one with hypomagnesemia and hypokalemia. Dysrhythmic events consisted of bigeminy, multifocal ventricular extrasystoles and torsades de pointes-like ventricular tachycardia. Electrocardiographic changes in acute pancreatitis in the absence of previous heart disease can occur in more than half of the cases. Antihistamines are medications that are known to produce heart rhythm disturbances, especially the second generation drugs astemizole and terfenadine. This is the first report of chloropyramine causing dysrhythmia. It seems that acute pancreatitis patients are especially prone to heart dysrhythmia caused by different factors such as electrolyte disturbances and pronounced vagal tone. Acute pancreatitis may be added to the list of risk factors with altered 'repolarization reserve', predisposing to drug-induced QT interval prolongation and possible torsades de pointes occurrence.


Assuntos
Arritmias Cardíacas/induzido quimicamente , Etilenodiaminas/efeitos adversos , Coração/efeitos dos fármacos , Antagonistas dos Receptores Histamínicos H1/efeitos adversos , Pancreatite Alcoólica/tratamento farmacológico , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/terapia , Eletrocardiografia , Etilenodiaminas/administração & dosagem , Antagonistas dos Receptores Histamínicos H1/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Torsades de Pointes/induzido quimicamente , Resultado do Tratamento
14.
Br J Dermatol ; 162(6): 1278-85, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20346018

RESUMO

BACKGROUND: It was recently shown that filaggrin gene (FLG) null mutations are positively associated with nickel sensitization. We have hypothesized that histidine-rich filaggrin proteins in the epidermis chelate nickel ions and prevent their skin penetration and exposure to Langerhans cells. Furthermore, we have proposed that the low degree of genetic predisposition to nickel sensitization found by a Danish twin study was explained by a high prevalence of ear piercing among participants resulting in 'bypassing' of the filaggrin proteins. OBJECTIVES: To investigate the association between FLG null mutations and (nickel) contact sensitization. METHODS: A random sample of 3335 adults from the general population in Denmark was patch tested and genotyped for R501X and 2282del4 in the FLG gene. RESULTS: The combined carrier frequency of FLG null mutations was 8·1%. Nickel, fragrance and contact sensitization to at least one allergen were not associated with FLG null mutations. A crude analysis on women who did not have ear piercings revealed a positive association between FLG null mutations and nickel sensitization [8·3% vs. 2·4%; odds ratio (OR) 3·71, 95% confidence interval (CI) 0·73-18·96] as well as between FLG null mutations and allergic nickel dermatitis (8·3% vs. 1·3%; OR 6·75, 95% CI 1·17-38·91). FLG mutation status and atopic dermatitis were positively associated with neomycin or ethylenediamine sensitization. CONCLUSIONS: This study suggests that FLG null mutations may be a risk factor for the development of nickel sensitization. However, ear piercing was a much stronger risk factor in our general population and we could therefore identify a positive association only in women without ear piercings. Contact sensitization to specific chemicals is related to treatment exposure.


Assuntos
Dermatite Atópica/genética , Proteínas de Filamentos Intermediários/genética , Níquel/toxicidade , Adolescente , Adulto , Idoso , Estudos Transversais , Dinamarca , Dermatite Atópica/imunologia , Etilenodiaminas/efeitos adversos , Feminino , Proteínas Filagrinas , Frequência do Gene , Genótipo , Humanos , Imunoglobulina E/análise , Masculino , Pessoa de Meia-Idade , Neomicina/efeitos adversos , Níquel/imunologia , Adulto Jovem
15.
Scand J Work Environ Health ; 35(6): 475-8, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19806278

RESUMO

OBJECTIVE: Occupational asthma (OA) is highly prevalent in industrialized countries and nearly 400 causal agents of this condition have been described to date. This study aims to describe the case of a patient who developed OA secondary to exposure to a surfactant agent comprised of alkylamine ethoxylate and a mixture of alkyleneoxy and ethylenediamine. METHODS: We present the case of a male worker in the meat industry suffering from OA resulting from exposure to a surfactant agent used to clean the animal carcass before it is quartered. We performed various tests on the individual, including: a chest computed tomography; total serum immunoglobulin E (IgE) and specific IgE tests against common pneumoallergens; pulmonary function studies; a methacholine test; and a specific inhalation challenge to the surfactant agent. RESULTS: The tests confirmed the diagnosis of OA. CONCLUSIONS: We discuss whether the amines present in the surfactant or the agent itself might be the cause of the condition. Because of the extensive use of surfactants in several types of industries, it is reasonable to think that their possible relationship with OA may have relevant health implications.


Assuntos
Matadouros , Aminas/efeitos adversos , Asma/induzido quimicamente , Detergentes/efeitos adversos , Doenças Profissionais/induzido quimicamente , Exposição Ocupacional , Alcanos/efeitos adversos , Etilenodiaminas/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade
18.
Immunopharmacol Immunotoxicol ; 25(4): 529-38, 2003 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-14686795

RESUMO

BACKGROUND: In the last few years, adverse reactions to mydriatic eyedrops have been investigated. However, is not still available a standardized protocol, capable of identify the pathogenetic mechanism. In the light of these findings we have evaluated the reliability of a protocol with well established concentration of specific allergens. METHODS: The diagnostic method includes the application of patch test series Gruppo Italiano Ricerca Dermatiti da Contatto e Ambientali (GIRDCA), medicaments, corticosteroids, local anesthetics, main eyedrops' excipients, pure active principles and extemporaneous preparations with mydriatic eyewashes. At the same time, skin prick test with a solution of atropine sulfate at 1 per thousand and an intradermal test with injection of atropine at 0.01 per thousand were carried out. RESULTS: After patch tests were removed, we detected seven positiveness to the phenylephrine, two to the benzalkonium chloride, one to thiomersal, one to the ethylendiamine and one to the atropine sulfate 1 per thousand. With intradermal tests we obtained three positiveness in patients who reported adverse reactions to atropine. CONCLUSIONS: Our results show that phenylephrine is frequently responsible for allergic conjunctivitis (53.8%). In the case of atropine, even though the limited number of patients suggests to perform more extensive studies, it emerges that our diagnostic protocol is safe and might be able to screen allergic reactions in the field of ophthalmopathies.


Assuntos
Conjuntivite Alérgica/etiologia , Soluções Oftálmicas/efeitos adversos , Testes do Emplastro/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Atropina/efeitos adversos , Atropina/imunologia , Compostos de Benzalcônio/efeitos adversos , Etilenodiaminas/efeitos adversos , Etilenodiaminas/imunologia , Feminino , Humanos , Testes Intradérmicos , Masculino , Pessoa de Meia-Idade , Fenilefrina/efeitos adversos , Fenilefrina/imunologia , Testes Cutâneos , Timerosal/efeitos adversos , Timerosal/imunologia
20.
Arch Bronconeumol ; 38(2): 93-4, 2002 Feb.
Artigo em Espanhol | MEDLINE | ID: mdl-11844442

RESUMO

A case of occupational asthma due to ethylenediamine, commonly used in different industrial fields, appearing in a man 56 years old who worked in the laundry powder industry is presented. The diagnosis was confirmed by specific bronchial challenge and appeared as a late bronchoconstrictive response. The appearance of inespecific bronchial responsiveness after the bronchial challenge is emphasized.


Assuntos
Asma/induzido quimicamente , Detergentes/efeitos adversos , Etilenodiaminas/efeitos adversos , Doenças Profissionais/induzido quimicamente , Exposição Ocupacional , Asma/diagnóstico , Testes de Provocação Brônquica , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Profissionais/diagnóstico , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA